Independent
Tenure on this board
1.3 yrs
Meeting calendar
IMVT · Annual meeting · Wednesday, September 2, 2026
Immunovant Inc
3 nominees · 3 ballot items.
Election of three directors; Ratification of Ernst & Young LLP as independent auditor for fiscal year ending March 31, 2027; Non-binding advisory approval of named executive officer compensation (“say-on-pay”).
Market cap
$8.0B
1Y TSR
+125.3%
Board grade
B-
Record date
Jul 8, 2026
Filing
DEF 14A
Filed Jul 22, 2026 · DEF 14A
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect three nominees—Jacob Bauer, Douglas Hughes, and Robert Susman—to the Board to serve until the 2027 Annual Meeting and until their successors are elected and qualified.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027.
- 3
Non-Binding, Advisory Vote on Executive Compensation (Say-on-Pay
ManagementBoard: FORApprove, on a non-binding advisory basis, the compensation of named executive officers as disclosed in the proxy statement.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
6.6 yrs
Independent
Tenure on this board
1.3 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, LP | 5.6% | 11,526,971 | $286M |
| 2 | FMR LLC | 4.7% | 9,630,249 | $239M |
| 3 | FMR LLC | 3.5% | 7,285,041 | $181M |
| 4 | BAKER BROS. ADVISORS LP | 2.7% | 5,457,881 | $136M |
| 5 | STATE STREET CORP | 2.2% | 4,537,929 | $113M |
| 6 | TCG Crossover Management, LLC | 2.2% | 4,457,988 | $111M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.8% | 3,704,905 | $92M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 1.8% | 3,620,050 | $90M |
| 9 | T. Rowe Price Investment Management, Inc. | 1.8% | 3,612,860 | $90M |
| 10 | ARMISTICE CAPITAL, LLC | 1.7% | 3,564,916 | $89M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Immunovant Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.3B
Reference
Frequently asked questions
- When is the Immunovant Inc 2026 annual meeting?
- Immunovant Inc (IMVT) holds its 2026 annual shareholder meeting on Wednesday, September 2, 2026.
- What is the record date for the Immunovant Inc 2026 meeting?
- The record date for the Immunovant Inc 2026 meeting is Wednesday, July 8, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Immunovant Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Immunovant Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Immunovant Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Immunovant Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.